| Zheng Wu, MD | |
|
2720 Clare Avenue, Suite A, Bremerton, WA 98310 | |
| (360) 479-6154 | |
| (360) 479-5728 |
| Full Name | Zheng Wu |
|---|---|
| Gender | Female |
| Speciality | Medical Oncology |
| Experience | 27 Years |
| Location | 2720 Clare Avenue, Suite A, Bremerton, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780830679 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | MD038723 (District Of Columbia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Harrison Medical Center | Bremerton, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Franciscan Medical Group | 0547173866 | 1115 |
News Archive
More than 106,000 body contouring procedures were performed in 2004, up 77 percent over the last five years according to statistics released by the American Society of Plastic Surgeons.
Both web-based and print-based decision aids appear to improve patients' informed decision making about prostate cancer screening up to 13 months later, but does not appear to affect actual screening rates, according to a study by Kathryn L. Taylor, Ph.D., of Georgetown University, Washington, D.C., and colleagues.
Early intervention facilitated by a digital health application for reporting symptoms of Chronic Obstructive Pulmonary Disease (COPD) provides key benefits for patients, according to the results of a Temple-led, two-year clinical study.
Two subset analyses from the landmark HORIZONS-AMI trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a GP IIb/IIIa inhibitor in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending artery (LAD), while in STEMI patients at highest risk for death, bivalirudin also confers the greatest mortality benefit.
Exact Sciences Corp. today announced that data being presented this afternoon at the annual meeting of the American Association of Clinical Chemistry demonstrates that its methylation specific technology, using a combination of DNA methylation markers, detected 100 percent of colorectal cancers and precancers at a specificity cutoff of 100 percent in a preliminary study with colorectal tissue.
› Verified 5 days ago
| Entity Name | Franciscan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093165334 PECOS PAC ID: 0547173866 Enrollment ID: O20031111000789 |
News Archive
More than 106,000 body contouring procedures were performed in 2004, up 77 percent over the last five years according to statistics released by the American Society of Plastic Surgeons.
Both web-based and print-based decision aids appear to improve patients' informed decision making about prostate cancer screening up to 13 months later, but does not appear to affect actual screening rates, according to a study by Kathryn L. Taylor, Ph.D., of Georgetown University, Washington, D.C., and colleagues.
Early intervention facilitated by a digital health application for reporting symptoms of Chronic Obstructive Pulmonary Disease (COPD) provides key benefits for patients, according to the results of a Temple-led, two-year clinical study.
Two subset analyses from the landmark HORIZONS-AMI trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a GP IIb/IIIa inhibitor in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending artery (LAD), while in STEMI patients at highest risk for death, bivalirudin also confers the greatest mortality benefit.
Exact Sciences Corp. today announced that data being presented this afternoon at the annual meeting of the American Association of Clinical Chemistry demonstrates that its methylation specific technology, using a combination of DNA methylation markers, detected 100 percent of colorectal cancers and precancers at a specificity cutoff of 100 percent in a preliminary study with colorectal tissue.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Zheng Wu, MD 4315 Thomas Brigade Ln, Fairfax, VA 22033-4279 Ph: () - | Zheng Wu, MD 2720 Clare Avenue, Suite A, Bremerton, WA 98310 Ph: (360) 479-6154 |
News Archive
More than 106,000 body contouring procedures were performed in 2004, up 77 percent over the last five years according to statistics released by the American Society of Plastic Surgeons.
Both web-based and print-based decision aids appear to improve patients' informed decision making about prostate cancer screening up to 13 months later, but does not appear to affect actual screening rates, according to a study by Kathryn L. Taylor, Ph.D., of Georgetown University, Washington, D.C., and colleagues.
Early intervention facilitated by a digital health application for reporting symptoms of Chronic Obstructive Pulmonary Disease (COPD) provides key benefits for patients, according to the results of a Temple-led, two-year clinical study.
Two subset analyses from the landmark HORIZONS-AMI trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a GP IIb/IIIa inhibitor in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending artery (LAD), while in STEMI patients at highest risk for death, bivalirudin also confers the greatest mortality benefit.
Exact Sciences Corp. today announced that data being presented this afternoon at the annual meeting of the American Association of Clinical Chemistry demonstrates that its methylation specific technology, using a combination of DNA methylation markers, detected 100 percent of colorectal cancers and precancers at a specificity cutoff of 100 percent in a preliminary study with colorectal tissue.
› Verified 5 days ago
Dr. Saurabh Rastogi, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2709 Hemlock St, Bremerton, WA 98310 Phone: 917-463-9130 | |
Kristin M Lee, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2600 Cherry Ave Ste 202, Bremerton, WA 98310 Phone: 360-479-2360 Fax: 253-985-2999 | |
Dr. Adeel Rahim Seyal, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2520 Cherry Ave, Bremerton, WA 98310 Phone: 360-377-3911 | |
George V Evanoff, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2771 Hemlock St, Suite 201, Bremerton, WA 98310 Phone: 360-377-7634 Fax: 360-479-6157 | |
Tavis J Taylor, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3036 Perry Ave, Suite A, Bremerton, WA 98310 Phone: 360-627-8493 Fax: 360-627-7920 | |
John David Lamberg, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2512 Wheaton Way, Bremerton, WA 98310 Phone: 360-782-3700 | |
Dr. Gary Joseph Gretch, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2620 Wheaton Way, Ste 1, Bremerton, WA 98310 Phone: 360-377-3923 Fax: 360-373-4988 |